XyloCor Therapeutics

XC001: Promising Gene Therapy for Refractory Angina Patients Published in Circulation: Cardiovascular Interventions

WAYNE, PA — XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that Circulation: Cardiovascular Interventions has published results from the Phase 1 portion of its Phase 1/2 clinical trial (EXACT) of …

XC001: Promising Gene Therapy for Refractory Angina Patients Published in Circulation: Cardiovascular Interventions Read More
XyloCor Therapeutics